TITLE

Dalteparin reduced recurrent venous thromboembolism more than oral anticoagulation in patients with cancer: COMMENTARY

AUTHOR(S)
Deitcher, Steven R.
PUB. DATE
January 2004
SOURCE
ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p10
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article focuses on a study regarding low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism (VTE) in patients with cancer, published in the 2003 issue of "New England Journal of Medicine." In patients with cancer and VTE, long-term warfarin therapy is challenging because of increased bleeding risk caused by thrombocytopenia or brain involvement and potential warfarin-drug interactions. The study shows that long-term dalteparin is more efficacious than, and as safe as, oral anticoagulation for prevention of recurrent VTE in cancer patients with acute thrombosis. The author says that similarly favorable results in cancer patients with acute VTE have also been recently reported with enoxaparin and tinzaparin.
ACCESSION #
12104541

 

Related Articles

  • Dalteparin reduced recurrent venous thromboembolism more than oral anticoagulation in patients with cancer.  // ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p10 

    This article focuses on a study regarding low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer, published in the 2003 issue of "New England Journal of Medicine." 676 patients who had active cancer and symptomatic proximal...

  • Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Palumbo, A.; Rajkumar, S. V.; Dimopoulos, M. A.; Richardson, P. G.; San Miguel, J.; Barlogie, B.; Harousseau, J.; Zonder, J. A.; Cavo, M.; Zangari, M.; Attal, M.; Belch, A.; Knop, S.; Joshua, D.; Sezer, O.; Ludwig, H.; Vesole, D.; Bladé, J.; Kyle, R.; Westin, J. // Leukemia (08876924);Feb2008, Vol. 22 Issue 2, p414 

    The incidence of venous thromboembolism (VTE) is more than 1‰ annually in the general population and increases further in cancer patients. The risk of VTE is higher in multiple myeloma (MM) patients who receive thalidomide or lenalidomide, especially in combination with dexamethasone or...

  • Low Molecular Weight Heparins as Antineoplastic Agents. Siragusa, Sergio // Recent Patents on Anti-Cancer Drug Discovery;Nov2008, Vol. 3 Issue 3, p159 

    There is an increasing interest in the potential role of low molecular weight heparins (LMWHs) in the management of cancer patients. These antithrombotic agents have generated particular excitement because they have been proved useful in both the prevention and treatment of venous...

  • The ethical decisions UK doctors make regarding advanced cancer patients at the end of life - the perceived (in) appropriateness of anticoagulation for venous thromboembolism: A qualitative study. Sheard, Laura; Prout, Hayley; Dowding, Dawn; Noble, Simon; Watt, Ian; Maraveyas, Anthony; Johnson, Miriam // BMC Medical Ethics;2012, Vol. 13 Issue 1, p22 

    Background: Cancer patients are at risk of developing blood clots in their veins - venous thromboembolism (VTE) - which often takes the form of a pulmonary embolism or deep vein thrombosis. The risk increases with advanced disease. Evidence based treatment is low molecular weight heparin (LMWH)...

  • Clots & cancer: Prophylaxis now the norm. Posey, L. Michael // Pharmacy Today;May2006, Vol. 12 Issue 5, p6 

    The article reports on community and health-system pharmacists preferring more aggressive venous thromboembolism (VTE) prophylaxis treatment for patients with various types of cancer, specially with subcutaneous low-molecular-weight heparins (LMWHs). VTE and cancer patients have higher risk of...

  • Review: low-molecular-weight heparin prevented recurrent VTE more than oral anticoagulants in patients with cancer. Howard, A. Fuchsia // Evidence Based Nursing;Oct2008, Vol. 11 Issue 4, p117 

    QUESTION In patients with cancer and venous thromboembolism (VTE), is long-term treatment with low-molecular-weight heparin (LMWH) effective and safe compared with oral anticoagulants? REVIEW SCOPE Studies selected compared LMWH with oral anticoagulants (vitamin K antagonists or ximelagatran)...

  • Patients with cancer at increased risk for thromboembolism. Raible, Eric // Cardiology Today;Jun2008, Vol. 11 Issue 6, p23 

    The article reports on the study made by Agnes Lee, associate professor of medicine at McMaster University in Ontario, suggesting that a regimen of dalteparin, which is a low-molecular-weight heparin, was effective at preventing recurrent thromboembolism in patients with cancer. This was...

  • New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients. Gerotziafas, Grigoris T.; Mahé, Isabelle; Elalamy, Ismail // Therapeutics & Clinical Risk Management;2014, Vol. 10, p423 

    Patients with cancer have a 6-7-fold higher risk of venous thromboembolism (VTE) as compared with non-cancer patients. Effective and safe anticoagulation for the prevention and treatment of VTE is the cornerstone of the management of patients with cancer, aiming to decrease morbidity and...

  • Coumarins: lowering target INR decreases complication risk.  // Reactions Weekly;5/29/2004, Issue 1003, p4 

    Discusses research being done on the effect of lowering the intensity of anticoagulant coumarins therapy on the risk of hemorrhage and thromboembolism. Reference to a study by M. Torn et al, published in the March 2004 issue of "Archives of Internal Medicine"; Decrease in incidence of bleeding...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics